<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062257</url>
  </required_header>
  <id_info>
    <org_study_id>CTRG-G15/02</org_study_id>
    <secondary_id>CDR0000304669</secondary_id>
    <secondary_id>NCI-6041</secondary_id>
    <nct_id>NCT00062257</nct_id>
  </id_info>
  <brief_title>Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer</brief_title>
  <official_title>A Phase II Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Therapeutics Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irofulven, use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well irofulven works in treating patients with&#xD;
      recurrent or metastatic gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate of patients with recurrent or metastatic gastric cancer&#xD;
           treated with irofulven.&#xD;
&#xD;
        -  Determine the toxicity profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a non-randomized, open-label, multicenter study.&#xD;
&#xD;
      Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 3 weeks&#xD;
      in the absence of disease progression, unacceptable toxicity, or static disease after 4&#xD;
      courses in the absence of clinical benefit.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study within 5-9&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irofulven</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed gastric adenocarcinoma&#xD;
&#xD;
               -  Recurrent or metastatic disease&#xD;
&#xD;
               -  Adenocarcinoma of the gastroesophageal junction eligible provided the majority of&#xD;
                  tumor bulk is below the junction&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 lesion at least 20 mm by conventional techniques OR at least 10 mm by&#xD;
                  spiral CT scan&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No active disseminated intravascular coagulation&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN (5 times ULN for patients with liver metastases)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to irofulven&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated carcinoma in&#xD;
             situ of the cervix or basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No other uncontrolled concurrent illness that would preclude study participation&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  Must have central or peripherally inserted central catheter&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for recurrent or metastatic disease&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant chemotherapy allowed provided disease relapsed more than&#xD;
             6 months after therapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for the&#xD;
             malignancy&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winnie Yeo</last_name>
    <role>Study Chair</role>
    <affiliation>Prince of Wales Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sydney Cancer Centre at Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center at Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute at National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins - Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre - Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2005</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irofulven</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

